Month: February 2024

NEW YORK, Feb. 22, 2024 (GLOBE NEWSWIRE) — FTAI Aviation Ltd. (NASDAQ: FTAI) (the “Company” or “FTAI”) today reported financial results for the fourth quarter and full year 2023. The Company’s consolidated comparative financial statements and key performance measures are attached as an exhibit to this press release. Financial Overview(in thousands, except per share data)    Selected Financial Results Q4’23    Net Income Attributable to Shareholders $      110,025    Basic Earnings per Ordinary Share from Continuing Operations $ 1.10    Diluted Earnings per Ordinary Share from Continuing Operations $ 1.09    Adjusted EBITDA(1) $ 162,331    _______________________________        1)  For definitions and reconciliations of non-GAAP measures, please refer to the exhibit to this press release.        Fourth...

eXp World Holdings Reports Q4 and Full-Year 2023 ResultseXp World Holdings, Inc. (Nasdaq: EXPI), or the “Company”, the holding company for eXp Realty®, Virbela and SUCCESS® Enterprises, today announced financial results for the fourth quarter and fiscal year ended Dec. 31, 2023.BELLINGHAM, Wash., Feb. 22, 2024 (GLOBE NEWSWIRE) — eXp World Holdings, Inc. (Nasdaq: EXPI), or the “Company”, the holding company for eXp Realty®, Virbela and SUCCESS® Enterprises, today announced financial results for the fourth quarter and fiscal year ended Dec. 31, 2023. Fourth Quarter and Full-Year 2023 Consolidated Financial Highlights as Compared to the Same Year-Ago Period:Full-year revenue decreased (7)% to $4.3 billion in 2023 with revenue of $983 million in the fourth quarter of 2023. Full-year gross profit decreased (12)% to $324.1...

SUGAR LAND, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) — Applied Optoelectronics, Inc. (NASDAQ: AAOI), a leading provider of fiber-optic access network products for the internet datacenter, cable broadband, telecom and fiber-to-the-home (FTTH) markets, today announced financial results for its fourth quarter and full year ended December 31, 2023. “We’re pleased by the continued progress we have made in improving our gross margin, which combined with expense management, allowed us to generate a small non-GAAP net income in the fourth quarter for the first time in many years,” said Dr. Thompson Lin, Applied Optoelectronics Inc. Founder, President and Chief Executive Officer. “While our fourth quarter revenue came in below our expectations, our gross margin outperformed our projections, and we generated non-GAAP EPS at the high end of...

WINTER PARK, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) — CTO Realty Growth, Inc. (NYSE: CTO) (the “Company” or “CTO”) today announced its operating results and earnings for the quarter and year ended December 31, 2023. Select Full Year 2023 HighlightsReported Net Income per diluted share attributable to common stockholders of $0.03 for the year ended December 31, 2023. Reported Core FFO per diluted share attributable to common stockholders of $1.77 for the year ended December 31, 2023. Reported AFFO per diluted share attributable to common stockholders of $1.91 for the year ended December 31, 2023. Invested $80.0 million into four retail property acquisitions and one land parcel, totaling 470,600 leasable square feet at a weighted-average going-in cash cap rate of 7.5%. Originated one first mortgage and provided seller financing through...

– Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $104.2 Million and $367.0 Million – – Ended 2023 with Cash, Cash Equivalents and Marketable Securities of $310.5 Million – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today reported its financial results for the quarter and full-year ended December 31, 2023, and provided a corporate update. “2023 was a banner year for Collegium Pharmaceutical....

Montevideo, Feb. 22, 2024 (GLOBE NEWSWIRE) — MercadoLibre, Inc. Reports Fourth Quarter 2023 Financial Results MONTEVIDEO, Uruguay; February 22, 2024; (GLOBE NEWSWIRE) — MercadoLibre, Inc. (Nasdaq: MELI) (http://www.mercadolibre.com) today reported financial results for the quarter ended December 31, 2023, in a Letter to Shareholders, which is now posted to the company’s Investor Relations website https://investor.mercadolibre.com. The Company will host its earnings video conference, as well as a conference call and audio webcast for any questions that investors may have, on February 22, at 5:00 p.m. Eastern Time. To access our video webcast and the live audio, investors, analysts and the market in general may access the following link at https://edge.media-server.com/mmc/p/6vd3zgg4/ and register at the platform to attend...

GAAP EPS of $0.67 in Q4 2023 Compared with $(0.55) in Q4 2022 GAAP EPS of $3.10 in Full-Year 2023 Compared with $0.43 in Full-Year 2022 GAAP Net Income of $89.9 million in Full-Year 2023 Compared with $0.2 million in Full-Year 2022 Q4 and Full-Year Adjusted EPS* of $1.25 and $4.31 in 2023 Compared with $1.17 and $3.10 in 2022 Introducing 2024 Full-Year Adjusted EPS* Guidance Range of $4.85-$5.15 CHARLOTTE, N.C., Feb. 22, 2024 (GLOBE NEWSWIRE) — SPX Technologies, Inc. (NYSE:SPXC) (“SPX”, the “Company”, “we” or “our”) today reported results for the fourth quarter and year ended December 31, 2023. Gene Lowe, President and CEO, remarked, “I am very pleased with our full-year 2023 results, including Adjusted EBITDA* growth of 50% and Adjusted EPS* growth of 39%, which is near the top end of our guidance range. Our strong Q4 performance...

Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort & initiated additional dose expansion cohorts with RLY-2608 400mg & 600mg Initiated RLY-2608 + fulvestrant + ribociclib triplet combination in PI3Kα-mutated HR+/HER2- metastatic breast cancer Approximately $750 million in cash, cash equivalents and investments at end of Q4 2023, expected to fund operations into second half of 2026 CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported fourth quarter and full year 2023 financial results and corporate highlights. “We made important progress across our portfolio during 2023, advancing...

Record Revenue and Adjusted EBITDA Margin for Analytics in 2023; Q4 2023 Sees Highest Free Cash Flow with Continued Consolidated Revenue Growth; Resilient Revenue Model Poised for Sustained Growth Emphasizing Strong Cash Generation in 2024 Amid Improving Market Dynamics TORONTO, Feb. 22, 2024 (GLOBE NEWSWIRE) — Altus Group Limited (ʺAltus” or “the Company”) (TSX: AIF), a leading provider of asset and fund intelligence for commercial real estate (“CRE”), announced today its financial and operating results for the fourth quarter and year ended December 31st, 2023, the approval by its Board of Directors of the payment of a cash dividend of $0.15 per common share for the first quarter ending March 31st, 2024, and its financial outlook for fiscal 2024. Unless otherwise indicated, all amounts are in Canadian dollars and percentages are...

Enrollment completed in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease; topline data expected in second half of 2024  On track to initiate first-in-human studies of ATH-1105 for the treatment of amyotrophic lateral sclerosis in first half of 2024 Strong balance sheet to support innovative pipeline through key inflection points BOTHELL, Wash., Feb. 22, 2024 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2023, and reviewed recent pipeline and business updates. “We’ve made important progress in our pursuit to advance potential new treatment options for neurodegenerative...